RARE Quote, Financials, Valuation and Earnings

Corcept Therapeutics, Inc. has a net margin of -62.32% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of 11.83%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -558.7% beat Corcept Therapeutics, Inc.'s return on equity of 14.97%.

Ultragenyx Pharmaceutical, Inc. has a consensus price target of $52.45, signalling upside risk potential of 133.63%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $67.40 which suggests that it could grow by 58.63%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Corcept Therapeutics, Inc., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Corcept Therapeutics, Inc..

Ultragenyx Pharmaceutical, Inc. has a beta of 0.248, which suggesting that the stock is 75.224% less volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.249, suggesting its less volatile than the S&P 500 by 75.089%.

Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical, Inc. quarterly revenues are $207M, which are larger than Corcept Therapeutics, Inc. quarterly revenues of $202.1M. Ultragenyx Pharmaceutical, Inc.'s net income of -$129M is lower than Corcept Therapeutics, Inc.'s net income of $23.9M. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while Corcept Therapeutics, Inc.'s PE ratio is 52.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 3.45x versus 6.77x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

CorMedix, Inc. has a net margin of -62.32% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of 10.9%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -558.7% beat CorMedix, Inc.'s return on equity of 67.96%.

Ultragenyx Pharmaceutical, Inc. has a consensus price target of $52.45, signalling upside risk potential of 133.63%. On the other hand CorMedix, Inc. has an analysts' consensus of $14.57 which suggests that it could grow by 106.69%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than CorMedix, Inc., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than CorMedix, Inc..

Ultragenyx Pharmaceutical, Inc. has a beta of 0.248, which suggesting that the stock is 75.224% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.406, suggesting its more volatile than the S&P 500 by 40.623%.

Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical, Inc. quarterly revenues are $207M, which are larger than CorMedix, Inc. quarterly revenues of $128.6M. Ultragenyx Pharmaceutical, Inc.'s net income of -$129M is lower than CorMedix, Inc.'s net income of $14M. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 3.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 3.45x versus 1.83x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Insmed, Inc. has a net margin of -62.32% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of -124.5%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -558.7% beat Insmed, Inc.'s return on equity of -192.35%.

Ultragenyx Pharmaceutical, Inc. has a consensus price target of $52.45, signalling upside risk potential of 133.63%. On the other hand Insmed, Inc. has an analysts' consensus of $214.32 which suggests that it could grow by 31.94%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Insmed, Inc., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Insmed, Inc..

Ultragenyx Pharmaceutical, Inc. has a beta of 0.248, which suggesting that the stock is 75.224% less volatile than S&P 500. In comparison Insmed, Inc. has a beta of 1.100, suggesting its more volatile than the S&P 500 by 10.036%.

Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insmed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. Insmed, Inc. pays out -- of its earnings as a dividend.

Ultragenyx Pharmaceutical, Inc. quarterly revenues are $207M, which are smaller than Insmed, Inc. quarterly revenues of $263.8M. Ultragenyx Pharmaceutical, Inc.'s net income of -$129M is higher than Insmed, Inc.'s net income of -$328.5M. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while Insmed, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 3.45x versus 52.50x for Insmed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -62.32% compared to Ultragenyx Pharmaceutical, Inc.'s net margin of 20.83%. Ultragenyx Pharmaceutical, Inc.'s return on equity of -558.7% beat Johnson & Johnson's return on equity of 34.46%.

Ultragenyx Pharmaceutical, Inc. has a consensus price target of $52.45, signalling upside risk potential of 133.63%. On the other hand Johnson & Johnson has an analysts' consensus of $241.08 which suggests that it could fall by -0.81%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Johnson & Johnson, analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Johnson & Johnson.

Ultragenyx Pharmaceutical, Inc. has a beta of 0.248, which suggesting that the stock is 75.224% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.337, suggesting its less volatile than the S&P 500 by 66.29%.

Ultragenyx Pharmaceutical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 2.15% to investors and pays a quarterly dividend of $1.30 per share. Ultragenyx Pharmaceutical, Inc. pays -- of its earnings as a dividend. Johnson & Johnson pays out 46.59% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Ultragenyx Pharmaceutical, Inc. quarterly revenues are $207M, which are smaller than Johnson & Johnson quarterly revenues of $24.6B. Ultragenyx Pharmaceutical, Inc.'s net income of -$129M is lower than Johnson & Johnson's net income of $5.1B. Notably, Ultragenyx Pharmaceutical, Inc.'s price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 21.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Ultragenyx Pharmaceutical, Inc. is 3.45x versus 6.24x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.